Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer (ALTER0302)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer (ALTER0302)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTER0302; ALTN-NSCLC
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 13 Feb 2018 Results assessing efficacy and tolerability of anlotinib in patients with non-small cell lung cancer, were published in the British Journal of Cancer.
    • 27 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Oct 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top